Hardip Sandhu


    Accepting PhD Students

    Calculated based on number of publications stored in Pure and citations from Scopus

    Research activity per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Vision Statement

    Early detection of drug-induced cardiac injury remains a major safety issue in drug development. I have been determined to improve the outcome of patients by implementing non-invasive early microRNA (miRNA) biomarkers of drug-induced cardiac injury and exploring the option of implementing adjunct therapy. In my team we work closely with cardiologists and oncologists on novel collaborative projects, and we have successfully assessed the role of cardiac injury associated miRNAs as biomarkers in cancer patients. These novel miRNAs biomarker findings hold an immense commercial potential as a platform to screen patients and candidate drugs for drug-induced cardiac injury adverse effects, and the Intellectual Property (IP) of this potential is currently being explored together with Pharmaceutical and Biotechnology partners.

    During my research carrier at the Faculty Research Centre for Sport, Exercise and Life Sciences (CSELS) I have excelled as a researcher in the field of Safety Pharmacology an Assistant Professor with Research Excellence Framework submissions, with a track record of first/last-author publications in high-impact journals and successful funding (i.e. Knowledge Exchange and Enterprise Network, European Regional Development Fund, British Pharmacological Society, The Lundbeck Foundation, Enterprise, Exchange, and Engagement Activities, and Coventry University Pump-Prime awards). In addition to my role at Coventry University as, I also take great pride in supporting the research community as a Reviewer of high impact journals and funding bodies (i.e. The European Commission, British Heart Foundation, and Breast Cancer Now).

    Research Interests

    The key research/IP projects that I am currently leading includes: therapy-induced cardiac injury miRNA biomarkers, the involvement of G-protein coupled receptors (GPCRs) during therapy-induced vascular injury, and anti-cancer therapy-induced cardiotoxicity (i.e. pathways involved and potential adjunct therapy options). The research projects are instinctive progression of my current research expertise, combining genomic and molecular biology techniques to determine the complex links between drug safety interactions and pathophysiological disease conditions. At Coventry University I have successfully supervised with completion: 2 PhD students, 1 MScR student, and 12 MSc students within the study timeframe and with excellent feedback. I am regularly recruiting students with aspirations to become excellent researchers.

    Expertise related to UN Sustainable Development Goals

    In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

    • SDG 3 - Good Health and Well-being

    Education/Academic qualification

    Degree, Risk factors for stroke – On pathways involved in vascular receptor regulation by tobacco and smoking, University of Copenhagen

    1 Jan 200811 Mar 2011

    Award Date: 11 Mar 2011

    MSc, NOD signalling system in Rhizobia, University of Copenhagen

    1 Aug 199930 Sept 2005

    Award Date: 30 Sept 2005

    MBA, Higher commercial course (Hhx), Niels Brock Copenhagen Business College

    1 Jul 19991 Aug 1998

    Award Date: 1 Jul 1999


    • RM Therapeutics. Pharmacology
    • Cardiovascular diseases
    • microRNAs
    • Adjunct therapy
    • Biomarker platforms
    • G-Protein-Coupled Receptors (GPCRs) Pharmacology
    • Safety Pharmacology
    • Cancer cardiotoxicity


    Dive into the research topics where Hardip Sandhu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
    • 1 Similar Profiles